Pyridazinone derivatives

US7507734B2 · kind B2 · utility

Assignee

• AVENTIS PHARMA S.A. · FR

Inventors

• Swen Hoelder · London, GB
• Gunter Muller · Frankfurt am Main, DE
• Karl Schoenafinger · Alzenau, DE
• David William Will · Schwalbach, DE
• Hans Matter · Langenselbold, DE
• Martin Bossart · Frankfurt am Main, DE
• Cecile Combeau · Fontenay-aux-Roses, FR
• Christine Delaisi · Châteauroux, FR
• Ingrid Sassoon · Villejuif, FR
• Anke Steinmetz · Vitry-sur-Seine, FR
• Didier Benard · Villiers-le-Bel, FR

Key dates

• Filing date: Nov 16, 2006
• Grant date: Mar 24, 2009
• Expiry date: Nov 16, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals.These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).